Physician Views: Benchmarking the leading multiple sclerosis brands

Which of the leading multiple sclerosis brands has had the biggest impact on changing treatment practice? Which product do prescribers consider the best overall? Which available therapy are physicians least likely to use and which is the most clinically differentiated versus its rivals? Which of the leading multiple sclerosis brands do prescribers expect to gain the biggest increase in use over the next five years? – we are snap-polling US and EU5-based neurologists to find out.

To be notified when poll results and analysis become available, please click here

Which product has had the biggest impact on changing treatment practice for multiple sclerosis?

Which treatment for multiple sclerosis is the best overall product?

Which treatment for multiple sclerosis are you least likely to use? (if a particular drug is not approved in your market please exclude it when considering your answer)

Which treatment for multiple sclerosis is the most clinically differentiated – in a positive way – versus the other therapies?

Which treatment for multiple sclerosis do you expect to gain the biggest increase in use over the next five years?

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.